Physician profile
Lana A Ecker
NPI 1982945200
$2,795.65
in general payments reported to CMS, 2019-2025
21 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $348 · 2023: $821 · 2024: $1,127 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.03 | 2024 | Wegovy |
| Gilead Sciences, INC. | $244.66 | 2022-2025 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $210.37 | 2023-2024 | Airsupra, Farxiga |
| Edwards Lifesciences Corporation | $153.53 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $131.09 | 2024 | Austedo Xr |
| Grifols USA, LLC | $125.00 | 2024 | Prolastin-C Liquid |
| Shield Therapeutics INC | $125.00 | 2023 | Accrufer |
| Ibsa Pharma INC. | $125.00 | 2024 | Tirosint |
| Horizon Therapeutics Plc | $124.95 | 2023 | Uplizna |
| Genzyme Corporation | $122.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $117.12 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $110.06 | 2022 | |
| Biogen, INC. | $107.28 | 2024 | |
| Novartis Pharmaceuticals Corporation | $106.37 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $103.65 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Genentech USA, INC. | $101.82 | 2023 | Evrysdi |
| Solventum Corporation | $100.00 | 2025 | V.A.C. Veraflo, V.A.C.Ulta |
| Alexion Pharmaceuticals, INC. | $88.55 | 2024 | Ultomiris |
| Atricure, INC. | $79.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.